Individual Investors Invested in Sino Medical Sciences Technology Inc. (SHSE:688108) up 17% Last Week, Insiders Too Were Rewarded
Individual Investors Invested in Sino Medical Sciences Technology Inc. (SHSE:688108) up 17% Last Week, Insiders Too Were Rewarded
Key Insights
主要見解
- Significant control over Sino Medical Sciences Technology by individual investors implies that the general public has more power to influence management and governance-related decisions
- 51% of the business is held by the top 14 shareholders
- 27% of Sino Medical Sciences Technology is held by insiders
- 個人投資者對華科醫療科技具有重要控制權,這意味着普通公衆更有力量影響管理和治理決策。
- 14位最大股東持有該業務的51%。
- 27%的華科醫療科技股權由內部人持有。
To get a sense of who is truly in control of Sino Medical Sciences Technology Inc. (SHSE:688108), it is important to understand the ownership structure of the business. With 42% stake, individual investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
要了解誰真正控制着華科醫療科技公司(SHSE:688108),重要的是了解該公司的所有權結構。個人投資者持有公司42%的股份,擁有最大的股份。也就是說,該集團是最有可能在股票上漲時受益(或在股票下跌時損失最慘)。
While individual investors were the group that benefitted the most from last week's CN¥513m market cap gain, insiders too had a 27% share in those profits.
儘管個人投資者在上週的人民幣51300萬市值增長中受益最多,但內部人員也分享了27%的利潤。
In the chart below, we zoom in on the different ownership groups of Sino Medical Sciences Technology.
在下面的圖表中,我們將重點關注中醫藥科技的不同所有權群體。
What Does The Institutional Ownership Tell Us About Sino Medical Sciences Technology?
機構所有權告訴我們有關中醫藥科技的什麼?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。
Sino Medical Sciences Technology already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Sino Medical Sciences Technology's historic earnings and revenue below, but keep in mind there's always more to the story.
中醫藥科技已經在股份登記冊上擁有機構。事實上,他們在公司擁有可觀的持股。這可能表明公司在投資界擁有一定的信譽度。然而,最好仍然謹慎依賴於機構投資者所謂的認可。他們有時也會犯錯。當多個機構持有一支股票時,總會存在它們參與'擁擠交易'的風險。當這種交易出錯時,多個方可能會競相快速賣出股票。這種風險在一個沒有增長曆史的公司中更高。您可以在下面看到中醫藥科技的歷史收益和營業收入,但請記住故事總是更多。
We note that hedge funds don't have a meaningful investment in Sino Medical Sciences Technology. With a 20% stake, CEO Jianhua Sun is the largest shareholder. Guotai Asset Management Company Limited is the second largest shareholder owning 6.8% of common stock, and Yanchao Guo holds about 5.5% of the company stock.
我們注意到對沖基金對中國醫學科技公司的投資並不重要。首席執行官孫建華持有20%的股份,是最大的股東。國泰資產管理有限公司是第二大股東,持有公司普通股的6.8%,而郭延超持有公司約5.5%的股份。
After doing some more digging, we found that the top 14 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.
經過進一步的調查,我們發現前14名股東持有該公司的51%的股份,這表明沒有單一的股東對該公司擁有重要的控制權。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
研究機構所有權是衡量和篩選股票預期表現的好方法。研究分析師的看法也可以達到同樣的效果。股票的分析師覆蓋率很低,但不多。因此,可以有更多的空間來增加其覆蓋範圍。
Insider Ownership Of Sino Medical Sciences Technology
中國醫學科技公司內部持股情況
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
雖然內部人員的具體定義可能是主觀的,但幾乎所有人都認爲董事會成員是內部人員。公司管理層應向董事會回答問題,後者應代表股東的利益。值得注意的是,有時高層管理人員也會成爲董事會成員。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。
Our most recent data indicates that insiders own a reasonable proportion of Sino Medical Sciences Technology Inc.. Insiders have a CN¥971m stake in this CN¥3.5b business. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.
我們最近的數據表明,內部人員擁有中國醫藥科技股份有限公司的一定比例。內部人員在這家市值35億的公司中擁有約97100萬人民幣的股份。我們認爲這顯示了與股東的契合度,但值得注意的是,該公司仍然相當小。一些內部人員可能是公司的創始人。您可以點擊這裏查看這些內部人員的買入和賣出情況。
General Public Ownership
一般大衆所有權
The general public-- including retail investors -- own 42% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
普通公衆,包括零售投資者,擁有42%的股份,因此不能被輕易忽視。雖然這樣的持股規模可能不足以在其利益方面左右政策決策,但他們仍然可以對公司政策產生集體影響。
Private Company Ownership
私有公司的所有權
We can see that Private Companies own 8.2%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
我們可以看到,私人公司擁有已發行股份的8.2%。但僅從這一事實本身很難得出任何結論,因此有必要研究擁有這些私人公司的人員。有時,內部人員或其他相關方可能通過獨立的私人公司持有公共公司的股份。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Sino Medical Sciences Technology better, we need to consider many other factors.
總是值得考慮持有一家公司股份的不同群體。但要更好地了解中華醫學科技,我們需要考慮許多其他因素。
I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.
我總是喜歡查看營業收入增長的歷史記錄,你也可以免費訪問這個詳細圖表中的歷史營收和收益圖表。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
最終,未來最重要。您可以在這份關於該公司分析師預測的免費報告中獲取有關信息。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。